MIR3926-1: A Potential Drug Target and Biomarker (G100500870)
MIR3926-1: A Potential Drug Target and Biomarker
Molecular Targets and Biomarkers
MIR3926-1, also known as ML-T086, is a small molecule drug target and biomarker that has been identified in the MIR3926 family of non-coding RNAs. This family consists of several highly conserved RNA molecules that have been shown to play important roles in various cellular processes, including gene regulation, RNA metabolism, and cell signaling. MIR3926-1 is a non-coding RNA molecule that has been shown to interact with the protein p21, also known as the tumor suppressor protein p53. This interaction between MIR3926-1 and p21 has been shown to promote the translation of MIR3926-1 into a protein that can interact with multiple cellular signaling pathways, including the TGF-β pathway.
The TGF-β pathway is a well-established signaling pathway that plays a central role in cell growth, differentiation, and cancer development. The TGF-β pathway is activated by the binding of the protein TGF-β1 to its receptor, which is a transmembrane protein that consists of two intracellular domains: the TGF-β receptor alpha chain and the TGF-β receptor beta chain. The TGF-β receptor alpha chain contains several critical signaling molecules, including the Smad family of proteins, which are involved in the regulation of cellular signaling pathways.
MIR3926-1 has been shown to interact with the TGF-β receptor alpha chain and has been shown to play a role in the regulation of TGF-β signaling pathway. This interaction between MIR3926-1 and TGF-β1 has been shown to promote the translation of MIR3926-1 into a protein that can interact with multiple cellular signaling pathways, including the TGF-β pathway. This suggests that MIR3926-1 may be a drug target or biomarker that can be targeted by small molecules or antibodies to inhibit the TGF-β pathway and potentially lead to the inhibition of cancer cell growth and progression.
In addition to its potential role in the TGF-β pathway, MIR3926-1 has also been shown to play a role in the regulation of cellular signaling pathways that are important for cell survival and differentiation. For example, MIR3926-1 has been shown to interact with the protein p300, which is a key transcription factor that is involved in the regulation of cellular signaling pathways that are important for cell survival and differentiation. This interaction between MIR3926-1 and p300 has been shown to promote the translation of MIR3926-1 into a protein that can interact with multiple cellular signaling pathways, including the TGF-β pathway.
MIR3926-1 has also been shown to play a role in the regulation of cellular signaling pathways that are important for cell growth and angiogenesis. For example, MIR3926-1 has been shown to interact with the protein FGF1, which is a key regulator of cellular signaling pathways that are important for cell growth and angiogenesis. This interaction between MIR3926-1 and FGF1 has been shown to promote the translation of MIR3926-1 into a protein that can interact with multiple cellular signaling pathways, including the TGF-β pathway.
In conclusion, MIR3926-1 is a non-coding RNA molecule that has been shown to interact with the TGF-β receptor alpha chain and has been shown to play a role in the regulation of multiple cellular signaling pathways, including the TGF-β pathway. These interactions between MIR3926-1 and critical signaling pathways suggest that MIR3926-1 may be a drug target or biomarker that can be targeted by small molecules or antibodies to inhibit the TGF-β pathway and potentially lead to the inhibition of cancer cell growth and progression. Further studies are needed to confirm these findings and to determine the full scope of
Protein Name: MicroRNA 3926-1
The "MIR3926-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR3926-1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR3926-2 | MIR3927 | MIR3928 | MIR3929 | MIR3934 | MIR3935 | MIR3936 | MIR3936HG | MIR3937 | MIR3938 | MIR3939 | MIR3940 | MIR3941 | MIR3942 | MIR3943 | MIR3944 | MIR3945 | MIR3945HG | MIR3960 | MIR3972 | MIR3973 | MIR3974 | MIR3976 | MIR3976HG | MIR3977 | MIR3978 | MIR409 | MIR410 | MIR411 | MIR412 | MIR421 | MIR422A | MIR423 | MIR424 | MIR425 | MIR4251 | MIR4252 | MIR4253 | MIR4254 | MIR4255 | MIR4256 | MIR4257 | MIR4258 | MIR4259 | MIR4260 | MIR4261 | MIR4262 | MIR4263 | MIR4264 | MIR4265 | MIR4266 | MIR4267 | MIR4268 | MIR4269 | MIR4270 | MIR4271 | MIR4272 | MIR4273 | MIR4274 | MIR4275 | MIR4276 | MIR4277 | MIR4278 | MIR4279 | MIR4280 | MIR4281 | MIR4282 | MIR4283-1 | MIR4283-2 | MIR4284 | MIR4285 | MIR4286 | MIR4287 | MIR4288 | MIR4289 | MIR429 | MIR4290 | MIR4291 | MIR4292 | MIR4293 | MIR4294 | MIR4295 | MIR4296 | MIR4297 | MIR4298 | MIR4299 | MIR4300 | MIR4300HG | MIR4301 | MIR4302 | MIR4303 | MIR4304 | MIR4305 | MIR4306 | MIR4307 | MIR4308 | MIR4309 | MIR431 | MIR4310 | MIR4311
